GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » YoY EBITDA Growth

ATOS (Atossa Therapeutics) YoY EBITDA Growth : 22.22% (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Atossa Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Atossa Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 22.22%.

Atossa Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was $-0.06.

Atossa Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Atossa Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics YoY EBITDA Growth Chart

Atossa Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.48 86.40 -25.14 -13.70 12.05

Atossa Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.50 - 9.68 13.56 22.22

Atossa Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Atossa Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.219--0.249)/ | -0.249 |
=12.05 %

Atossa Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.056--0.072)/ | -0.072 |
=22.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » YoY EBITDA Growth
Comparable Companies
CRBP ORMP SGMT ZURA HLVX ZNTL COYA VXRT KYTX TCRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ATOS:Mexico YAG2:Germany YAG2:Germany
Address
10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125
Website
https://www.atossatherapeutics.com
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Executives
H. Lawrence Remmel director C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Heather Rees officer: SVP, Finance and Accounting C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE WA 98104
Kyle Guse officer: CFO & General Counsel C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98102
Shu-chih Chen director, 10 percent owner, officer: Chief Scientific Officer C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112
Steven C Quay director, 10 percent owner, officer: CEO 22026 20TH AVENUE S E, SUITE 102, BOTHELL WA 98021
Scott Youmans officer: Chief Operating Officer ATOSSA GENETICS INC., 2345 EASTLAKE AVE. E, SUITE 201, SEATTLE WA 98102
John E Sawyer officer: See Remarks C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98021
Christopher S. Destro officer: SVP, Sales and Marketing C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Peter J. Carbonaro officer: Sr. Vice President, Operations C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Ben R Chen officer: Sr. VP of Glob. Reg. Affairs 1616 EASTLAKE AVENUE EAST, SUITE 510, SEATTLE WA 98102
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Alexander D Cross director C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO CA 92121
Stephen J Galli director C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
John Barnhart director C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112